High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.

ABSTRACT:

Background

Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high. The molecular mechanism of this resistance has not been fully elucidated. High mobility group box 1 (HMGB1) is a multifaceted protein that plays a key role in the proliferation, apoptosis, metastasis and angiogenesis of HCC cells. In addition, HMGB1 has been suggested to contribute to chemotherapy resistance in tumours, including lung cancer, osteosarcoma, neuroblastoma, leukaemia, and colorectal cancer. This study investigated the association between HMGB1 and sorafenib resistance in HCC.

Methods

HepG2 cells with HMGB1 knockdown or ove

SUBMITTER: Xiao Y 

PROVIDER: S-EPMC5731191 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature